Business Context and Reporting Period
Company: ProMIS Neurosciences Inc. (PMN)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies and vaccines for neurodegenerative diseases, including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and amyotrophic lateral sclerosis (ALS). The company utilizes a proprietary technology platform to target toxic, misfolded proteins. Key product candidates include PMN310 (AD), PMN267 (ALS), and PMN442 (DLB/Parkinson's).
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(19,974,029) | $(11,729,656) |
| Net Loss Per Share (Basic & Diluted) | $(2.54) | $(1.28) |
| Operating Expenses | $20,911,296 | $12,266,399 |
| Research & Development (R&D) | $16,492,799 | $9,521,793 |
| General & Administrative (G&A) | $4,418,497 | $2,744,606 |
| Cash and Short-Term Investments | $53,463,033 | N/A |
| Accumulated Deficit | $(150,380,249) | N/A |
| Net Cash Used in Operating Activities | $(22,768,585) | N/A |
| Net Cash Provided by Financing Activities | $70,081,309 | N/A |
Material Changes vs. Prior Period
- Financing Activity: In January 2026, the Company completed a private placement (PIPE) raising net proceeds of approximately $70.1 million. This resulted in a significant increase in cash balances from $6.1 million at December 31, 2025, to $53.4 million at June 30, 2026.
- Operating Expenses: Total operating expenses increased by $3.3 million (18%) for the six months ended June 30, 2026, compared to the same period in 2025.
- R&D Expenses: Increased by $2.3 million (16%), primarily driven by full activity in the PMN310 Phase 1b clinical trial and increased employee salaries/benefits due to bonus expenses.
- G&A Expenses: Increased by $1.0 million (29%), driven by higher employee salaries/benefits (bonus expense), increased professional/consulting fees (legal and recruiting), and patent expenses.
- Other Income: Increased by $0.8 million to $0.9 million for the six-month period, attributable to higher interest income resulting from increased cash balances.
- Share Count: Common shares outstanding increased from 2.15 million (Dec 31, 2025) to 8.97 million (June 30, 2026) due to the January 2026 PIPE issuance.
Guidance, Outlook, and Risks
- Clinical Progress (PMN310): The Company reported positive blinded six-month interim safety and biomarker results from the PRECISE-AD Phase 1b trial. No ARIA-E (Amyloid-Related Imaging Abnormalities - Edema) was observed. Unblinded 12-month topline data is expected in Q1 2027.
- Liquidity Outlook: Management expects existing cash and short-term investments to be sufficient to fund operations and capital expenditures through 2027. However, the Company anticipates continued losses and will require additional funding for future clinical activities.
- Risks:
- Capital Requirements: Significant additional funding is required to advance clinical trials and commercialization. Failure to secure financing could force delays or termination of programs.
- Development Risk: No assurance that product candidates will successfully complete clinical trials or obtain regulatory approval.
- Going Concern: While currently funded through 2027, the Company has a history of losses and an accumulated deficit of $150.4 million.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $53.4 million cash balance to cover the projected burn rate through 2027, considering potential acceleration of clinical trials.
- PMN310 Trial Data: Monitor the release of unblinded 12-month topline data expected in Q1 2027 for efficacy and safety confirmation.
- Dilution Risk: Assess the impact of the recent 4x increase in share count (from 2.15M to 8.97M) and the existence of ~9.3 million outstanding warrants on future equity dilution.
- Expense Trajectory: Review the trend in R&D and G&A expenses, specifically the impact of bonus expenses and clinical trial scaling, on future cash consumption.
- Regulatory Status: Confirm the status of the FDA Fast Track designation for PMN310 and any updates regarding IND-enabling studies for PMN267 and PMN442.